Shahram Hejazi, PhD
Dr. Shahram Hejazi is a life science entrepreneur and executive with general management experience in early-stage ventures and large global companies. Currently, he is a Venture Partner with BioAdvance, where he focuses on investments in devices, diagnostics, research tools, and health IT. At BioAdvance he is a Board Director for Enzium, Inc., Optofluidics, Inc., Leversense LLC, Infrascan, Inc., and Eagle Vision Pharmaceutical, Inc. He is also the founder and CEO of Optimeos Life Sciences LLC, a company based on a nanoparticle technology licensed from Princeton University. In addition to his Board responsibilities at BioAdvance, Shahramis on the Boards of SibTech Inc., Therognostic Technologies Inc., and Integral Molecular Inc.
Prior to these positions, (2004-2008), Shahram was the President of Kodak’s Molecular Imaging division, where he had global responsibility for R&D, manufacturing, operations, sales, marketing, and service of three diverse business lines, eventually selling it to a private equity firm. Before Kodak (2001-2004), he was the CEO of Zargis Medical Corp. (a Siemens spinoff) where he led the company from raising capital and the technology development to completion of several clinical trials, successful FDA regulatory approval and product launch – the company was later sold to 3M. Prior to Zargis (1996-2001), Shahram was the Global Head of the Strategic Business Development at Siemens medical, responsible for identifying early stage growth/investment opportunities and new business development. Earlier in his career, Shahram held R&D management positions at Kodak and IBM. Shahram has a PhD in electrical engineering with an emphasis in biophysics (SUNY at Buffalo) and an executive business education (Stanford University).